Organic Active Ingredients TRIZ Cases

This case uses pre-warmed saline, 30–45°C holding, and citrate-buffered pH control to limit decomposition and impurities.

This case uses oral fasudil or hydroxyfasudil to treat PBA across dementia, stroke, and traumatic brain injury.

This case pairs a soluble remdesivir liquid with a soft-mist nebulizer to enable accurate pulmonary dosing for viral treatment.

MSI testing with multiplex PCR and capillary electrophoresis guides WRN helicase inhibition for nonresponsive tumors.

This case uses 2′-fluoro, 2′-O-methyl, and terminal phosphorothioate patterns to stabilize dsRNA without blocking cleavage.

Genetic profiling guides PCSK9 inhibition or LDLR agonism to address sepsis severity and reduce MODS risk.

This case uses botanical and bacterial extracts to support aging skin, barrier function, and acne care with less irritation.

Defined acid cocrystals address AZD1656 polymorphism and milling adhesion while supporting solubility, stability, and bioavailability.

This case combines β-glucan with immune checkpoint antibodies to reduce tumor volume and activate cytotoxic T cells.

Novel antibacterial compounds paired with efflux pump inhibitors target carbapenem-resistant bacteria and improve treatment effectiveness.

Combines a quinoline derivative with other drugs for resistant sarcoma treatment.

This case shows how dual SHP-2 and KRAS G12C inhibition can improve efficacy across resistant KRAS mutant cell lines.

This composition combines aldehyde donors, anticoagulants, chelators, and polysaccharides to preserve cfRNA, cfDNA, and vesicles.

Hyaluronic acid nanoparticles deliver NOX inhibitors to cancer cells, sensitizing them to chemotherapy and limiting healthy-tissue damage.

This case combines plinabulin with checkpoint inhibitors or chemotherapy to restore antigen presentation and treat refractory tumors.

A modified heterocyclic THR-β agonist improves lipid metabolism and liver enrichment while limiting cardiac and thyroid-axis effects.

Benzimidazole and aza-benzimidazole compounds activate GLP-1R for oral dosing, stimulating insulin and suppressing glucagon.

This case uses Compound 1 dosing to address inadequate responses or intolerance while reducing peripheral blood lymphocyte counts.

Cellulose-based hydrogels combine thermoresponsive injection, sustained drug release, mechanical support, and biodegradability.

This case targets NT5C2 R367Q mutant lymphoblasts with inhibitors that synergize with 6-MP to reduce cell viability.

Fluorescent PGOs serve as PGT substrates and labels, supporting infection detection and resistance profiling without mammalian interference.

This case uses CCN5 or its encoding nucleic acid to reverse retinal pigment epithelial fibrosis and mitigate vision loss.

This case pairs intralesional Rose Bengal with systemic therapy to ablate refractory pediatric solid tumors and enhance immune response.

This case uses modified antisense oligonucleotides to inhibit ANGPTL7, targeting intraocular pressure reduction for glaucoma.

This case uses BRD9 inhibitors to address uLMS therapy resistance by reducing proliferation, inducing apoptosis, and limiting recurrence.

This case uses acetazolamide analogues to inhibit VRE carbonic anhydrase without disrupting gut microbiota balance.

This case uses specific UDP-glucosyltransferases to form water-soluble cannabinoid glycosides, reducing reliance on unstable nanoemulsions.

This case uses selected Ulva polysaccharides to increase NK and INFγ-producing cells and limit bacterial spread after trauma.

This case uses delayed near-infrared fluorescence analysis to improve reticular pseudodrusen detection and guide treatment discovery.

Explore cyclopentane derivatives that inhibit TRPC6 and TRPC3, expanding targeted options for FSGS and related disorders.

This case uses oral fospropofol salts and acid co-administration to improve bioavailability and reduce patient variability in migraine care.

This case shows how crystalline DMT salts improve aqueous solubility, stability, and melting point for drug formulation.

Induction, drug-free, and maintenance periods with beta interferon sustain efficacy while reducing Cladribine adverse events.

This case combines protected intermediates, merged coupling, and controlled crystallization to reduce impurities in maribavir synthesis.

Hydrolysis, salt formation, anti-solvent addition, and cooling produce a stable free-plate crystal habit with improved filtration.

Modular diazabicyclooctanone structures broaden serine β-lactamase inhibition, including OXA carbapenemases, for antibiotic combinations.

Gamma-irradiated or heat-killed CD20 feeder cells stimulate antigen-specific T cells for targeted destruction of lymphoma cells.

This case combines BTK binding with E3 ligase recruitment for oral proteasomal degradation in resistant B cell disease.

This case develops pyridazin-3-yl phenol inhibitors that block NLRP3 inflammasome activity while improving metabolic stability.

This case uses covalently linked oligonucleotide subunits to reduce glomerular filtration, extend circulation, and improve payload delivery.

This case uses ibudilast or analogs to modulate NCS1-calcium signaling and protect cells from Wolfram Syndrome progression.

Localized substituent changes tune TLR-8 potency and selectivity in diamino pyrido pyrimidine compounds.

This case uses the 2S,4R enantiomer and titrated co-medication dosing to inhibit cortisol synthesis while limiting interactions.

This case develops small-molecule GLP-1R agonists for oral dosing, improving pharmacokinetics, glucose tolerance, and food-intake reduction.

This case combines folate targeting, CD3 engagement, and PEGylation to improve tumor selectivity and limit toxicity.

See how water-soluble polymers, sugars, and plasticizers help FDM objects reach 80% active-component elution within 85 minutes.

Colchicine-site inhibitors disrupt microtubules while improving solubility and reducing toxicity in drug-resistant cancer models.

Controlled flavonoid levels and pH preserve water-like taste while oxygen-impermeable packaging improves shelf stability.

This case uses synthetic CBG quinone analogs with CB2 interaction and MAO inhibition to address inconsistent neurological treatment options.

This case uses periodic oral cladribine dosing to address ineffective RRMS treatments for PPMS and SPMS, reducing relapses and progression.